Pamela Carroll, PhD, has joined Roche as head of the Nutley Oncology Discovery Site and Global Pathways Biology within Pharma Research and Early Development.
MedImmune’s Frederick Manufacturing Center Expansion Facility is the winner of the 2011 Facility of the Year Awards program.
Aslan Pharmaceuticals and Bristol-Myers Squibb Co. have partnered to develop BMS-777607, BMS’ investigational small molecule inhibitor of the MET receptor tyrosine kinase for treatment of solid tumors.
Ancor Capital Partners acquired WellSpring Pharmaceuticals, a manufacturer and marketer of specialty prescription and over-the-counter products in North America, as well as contract manufacturing services.
Finding an efficient way to produce Taxol, a highly successful drug used to treat ovarian, breast, lung, liver, and other cancer types, in the laboratory remains one of the most sought-after goals in organic chemistry.
Tibotec Pharmaceuticals announced the final analysis of Pillar, a Phase 2b study of the investigational hepatitis C virus NS3/4A protease inhibitor TMC435 in patients with chronic genotype 1 HCV.
A jumping gene with the fairy tale name 'Sleeping Beauty' has helped to unlock vital clues for researchers investigating the genetics of colorectal cancer.
PerkinElmer, Inc. introduced the NexION Enhanced Security Software, to streamline regulatory compliance by pharmaceutical companies. The ES Software platform was developed for users of PerkinElmer's NexION 300 ICP-MS system.
Control Company’s Traceable dishwasher metal thermometer reports the maximum and minimum temperatures insures proper cleaning by providing proof of meeting the temperature regulation of 180°F during dishwashing.
Horizon Discovery Ltd. announced a partnership with Promega Corporation centering on the delivery of endogenous gene reporting capabilities, in the form of Promega’s luciferase and HaloTag reporters, using Horizon’s genome editing technology.
Ardea Biosciences Inc. reported a larger third-quarter loss as it continued to develop its gout drug candidates and its revenue decreased. Ardea said its net loss amounted to $22.5 million, or 84 cents per share, for the three months ended Sept. 30.
Nabi Biopharmaceuticals announced that NicVAX did not meet its primary endpoint in the second of two confirmatory Phase 3 clinical trials. An assessment of the trial data showed that no statistical difference between the NicVAX and placebo groups.
More than 2 million new U.S. patients will be eligible to receive a next-generation blood thinner drug called Xarelto, after the Food and Drug Administration approved the medication to treat a common heart problem that can lead to stroke.
Pharmaceutical company Inhibitex Inc. said early data from a mid-stage study showed that a 200-milligram dose of its potential hepatitis C treatment did well in reducing the virus in patients.
Drug developer Amag Pharmaceuticals Inc. said its CEO had resigned and the company will begin a restructuring that includes cutting about 25% of its jobs and as much as $25 million in operating expenses.